Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic mesenchymal stem cells for moderate COVID-19 in older adults
RBR-65trt53Phase 2Unknown
- Sponsor
- R-Crio
- Start
- Apr 2021
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MSV alogénicas in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by R-Crio. Status: unknown.
02
Drugs
MSV alogénicas
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on RBR-65trt53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-65trt53.